These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20307063)

  • 21. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
    Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
    J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
    Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.
    Christoph T; Grünweller A; Mika J; Schäfer MK; Wade EJ; Weihe E; Erdmann VA; Frank R; Gillen C; Kurreck J
    Biochem Biophys Res Commun; 2006 Nov; 350(1):238-43. PubMed ID: 16996476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.
    Wang X; Chakrabarti PP; Ognyanov VI; Pettus LH; Tamir R; Tan H; Tang P; Treanor JJ; Gavva NR; Norman MH
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6539-45. PubMed ID: 17937985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRPV1 desensitisation and endogenous vanilloid involvement in the enhanced analgesia induced by capsaicin in inflamed tissues.
    Baamonde A; Lastra A; Juarez L; Hidalgo A; Menéndez L
    Brain Res Bull; 2005 Nov; 67(6):476-81. PubMed ID: 16216696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
    Quintanar-Audelo M; Fernández-Carvajal A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Albericio F
    J Med Chem; 2007 Nov; 50(24):6133-43. PubMed ID: 17985859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
    Knotkova H; Pappagallo M; Szallasi A
    Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
    Swanson DM; Dubin AE; Shah C; Nasser N; Chang L; Dax SL; Jetter M; Breitenbucher JG; Liu C; Mazur C; Lord B; Gonzales L; Hoey K; Rizzolio M; Bogenstaetter M; Codd EE; Lee DH; Zhang SP; Chaplan SR; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):1857-72. PubMed ID: 15771431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY; Gavva NR
    Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA interference-mediated knock-down of transient receptor potential vanilloid 1 prevents forepaw inflammatory hyperalgesia in rat.
    Kasama S; Kawakubo M; Suzuki T; Nishizawa T; Ishida A; Nakayama J
    Eur J Neurosci; 2007 May; 25(10):2956-63. PubMed ID: 17509082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
    Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
    Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath.
    Tékus V; Bölcskei K; Kis-Varga A; Dézsi L; Szentirmay E; Visegrády A; Horváth C; Szolcsányi J; Petho G
    Eur J Pharmacol; 2010 Sep; 641(2-3):135-41. PubMed ID: 20534382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models.
    Joshi SK; Honore P; Hernandez G; Schmidt R; Gomtsyan A; Scanio M; Kort M; Jarvis MF
    J Pain; 2009 Mar; 10(3):306-15. PubMed ID: 19070548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of transient receptor potential vanilloid subfamily 1 to endothelin-1-induced thermal hyperalgesia.
    Kawamata T; Ji W; Yamamoto J; Niiyama Y; Furuse S; Namiki A
    Neuroscience; 2008 Jun; 154(3):1067-76. PubMed ID: 18495351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist.
    Maher MP; Bhattacharya A; Ao H; Swanson N; Wu NT; Freedman J; Kansagara M; Scott B; Li DH; Eckert WA; Liu Y; Sepassi K; Rizzolio M; Fitzgerald A; Liu J; Branstetter BJ; Rech JC; Lebsack AD; Breitenbucher JG; Wickenden AD; Chaplan SR
    Eur J Pharmacol; 2011 Aug; 663(1-3):40-50. PubMed ID: 21575625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naïve, carrageenan-inflamed and neuropathic rats.
    Jhaveri MD; Elmes SJ; Kendall DA; Chapman V
    Eur J Neurosci; 2005 Jul; 22(2):361-70. PubMed ID: 16045489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
    Brown BS; Keddy R; Zheng GZ; Schmidt RG; Koenig JR; McDonald HA; Bianchi BR; Honore P; Jarvis MF; Surowy CS; Polakowski JS; Marsh KC; Faltynek CR; Lee CH
    Bioorg Med Chem; 2008 Sep; 16(18):8516-25. PubMed ID: 18722778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats.
    McGaraughty S; Chu KL; Faltynek CR; Jarvis MF
    J Neurophysiol; 2006 Jan; 95(1):18-25. PubMed ID: 16162831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain.
    Endres-Becker J; Heppenstall PA; Mousa SA; Labuz D; Oksche A; Schäfer M; Stein C; Zöllner C
    Mol Pharmacol; 2007 Jan; 71(1):12-8. PubMed ID: 17005903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient receptor potential vanilloid 1 mediates hyperalgesia and is up-regulated in rats with chronic pancreatitis.
    Xu GY; Winston JH; Shenoy M; Yin H; Pendyala S; Pasricha PJ
    Gastroenterology; 2007 Oct; 133(4):1282-92. PubMed ID: 17698068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.